| pubmed-article:19552619 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C0025598 | lld:lifeskim |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C2917389 | lld:lifeskim |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C1709518 | lld:lifeskim |
| pubmed-article:19552619 | lifeskim:mentions | umls-concept:C2746078 | lld:lifeskim |
| pubmed-article:19552619 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:19552619 | pubmed:dateCreated | 2009-7-20 | lld:pubmed |
| pubmed-article:19552619 | pubmed:abstractText | Linagliptin (BI 1356) is a novel, orally available inhibitor of dipeptidyl peptidase-4 (DPP-4). Linagliptin improves glycaemic control in type 2 diabetic patients by increasing the half-life of the incretin hormone glucagon-like peptide-1 (GLP-1). Linagliptin is expected to be used as monotherapy or in combination with other antihyperglycaemic agents. This study was conducted to investigate potential pharmacokinetic or pharmacodynamic interactions between linagliptin and metformin. | lld:pubmed |
| pubmed-article:19552619 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19552619 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19552619 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19552619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19552619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19552619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19552619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19552619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19552619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19552619 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19552619 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19552619 | pubmed:issn | 1473-4877 | lld:pubmed |
| pubmed-article:19552619 | pubmed:author | pubmed-author:RingAA | lld:pubmed |
| pubmed-article:19552619 | pubmed:author | pubmed-author:DugiK AKA | lld:pubmed |
| pubmed-article:19552619 | pubmed:author | pubmed-author:PadulaSS | lld:pubmed |
| pubmed-article:19552619 | pubmed:author | pubmed-author:Graefe-ModyE... | lld:pubmed |
| pubmed-article:19552619 | pubmed:author | pubmed-author:WithopfBB | lld:pubmed |
| pubmed-article:19552619 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19552619 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:19552619 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19552619 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19552619 | pubmed:pagination | 1963-72 | lld:pubmed |
| pubmed-article:19552619 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:meshHeading | pubmed-meshheading:19552619... | lld:pubmed |
| pubmed-article:19552619 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19552619 | pubmed:articleTitle | Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. | lld:pubmed |
| pubmed-article:19552619 | pubmed:affiliation | Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, D-88397 Biberach/Riss, Germany. EvaUlrike.Graefe-Mody@boehringer-ingelheim.com | lld:pubmed |
| pubmed-article:19552619 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19552619 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19552619 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
